Global Wealth Management Investment Advisory Inc. Has $1.79 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Global Wealth Management Investment Advisory Inc. raised its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 26.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,867 shares of the medical research company's stock after buying an additional 1,438 shares during the period. Global Wealth Management Investment Advisory Inc.'s holdings in Amgen were worth $1,790,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Lansing Street Advisors grew its stake in shares of Amgen by 1.3% during the third quarter. Lansing Street Advisors now owns 2,582 shares of the medical research company's stock worth $832,000 after purchasing an additional 32 shares during the period. Unionview LLC lifted its stake in Amgen by 3.8% in the third quarter. Unionview LLC now owns 876 shares of the medical research company's stock valued at $282,000 after buying an additional 32 shares during the period. AM Investment Strategies LLC boosted its holdings in Amgen by 0.4% during the third quarter. AM Investment Strategies LLC now owns 7,471 shares of the medical research company's stock worth $2,407,000 after buying an additional 33 shares during the last quarter. Avidian Wealth Enterprises LLC grew its position in shares of Amgen by 0.6% during the 3rd quarter. Avidian Wealth Enterprises LLC now owns 5,863 shares of the medical research company's stock worth $1,889,000 after buying an additional 33 shares during the period. Finally, Beacon Financial Advisory LLC increased its stake in shares of Amgen by 4.6% in the 3rd quarter. Beacon Financial Advisory LLC now owns 769 shares of the medical research company's stock valued at $248,000 after acquiring an additional 34 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Jefferies Financial Group restated a "buy" rating and set a $380.00 price objective on shares of Amgen in a report on Tuesday, November 12th. Citigroup decreased their price target on shares of Amgen from $310.00 to $295.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Piper Sandler Companies reaffirmed an "overweight" rating and set a $310.00 price objective on shares of Amgen in a research note on Thursday, January 2nd. Redburn Partners decreased their target price on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Finally, Truist Financial dropped their price target on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research report on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Amgen currently has an average rating of "Hold" and a consensus price target of $314.09.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.69% of the stock is currently owned by corporate insiders.

Amgen Stock Up 0.4 %

AMGN traded up $1.25 during trading on Monday, reaching $294.79. 2,375,450 shares of the stock were exchanged, compared to its average volume of 3,280,951. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.96 and a current ratio of 1.26. The stock's 50 day moving average price is $272.26 and its two-hundred day moving average price is $302.77. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The stock has a market cap of $158.46 billion, a P/E ratio of 39.05, a price-to-earnings-growth ratio of 3.01 and a beta of 0.56.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities analysts expect that Amgen Inc. will post 20.59 EPS for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.23%. This is a boost from Amgen's previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen's dividend payout ratio (DPR) is presently 119.21%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.